A Study of Trilaciclib Combined With Chemotherapy in the Treatment of Diffuse Large B-Cell Lymphoma Patients

This study tests a drug called trilaciclib given alongside standard R-CHOP chemotherapy in people newly diagnosed with diffuse large B-cell lymphoma (DLBCL), a common and aggressive type of blood cancer. Trilaciclib is designed to protect bone marrow cells from chemotherapy damage, potentially reducing low blood count side effects. **You may be eligible if:** - You are 18 or older with newly diagnosed, confirmed DLBCL - You have not received any treatment for DLBCL yet - You have a low-to-intermediate risk score (IPI 0-2) and good performance status (ECOG 0-2) - You have at least one measurable tumor - Your organ function is adequate and you have an expected survival over 3 months - Women of childbearing potential must have a negative pregnancy test before the first dose **You may NOT be eligible if:** - You have already received treatment for DLBCL - You have poor organ function - You have received certain blood-boosting medications (G-CSF, EPO, TPO, IL-11) or transfusions recently Talk to your doctor to see if this trial is right for you.